A FORMULATION INTENDED FOR TREATMENT OF INTESTINAL MALABSORPTION
Creators: name: Alkoclar, Erdal Can
Publisher: name: Zenodo
Year: 2020
Subjects: GLUT4 Insulin Sensititizer Amylase

description: The present invention herewith is related to a formulation developed for treatment of intestinal malabsorption. <strong>Background of the Related Technology</strong> As of today, intestine is referred to as the section between the stomach and anus along the gastro-intestinal tract, which consists of two sections in humans and other mammals; small intestine and large intestine. Malabsorption is the disorder related to inability of absorption of nutrients from small intestine and sometimes this might be related to the pancreas. Some of the causes for this disorder may include the following: Coeliac Disease, lactose intolerance, fructose malabsorption, secretion disorders related to pernicious anemia of pancreas (short bowel syndrome, radiation fibrosis (generally observed after treatment of cancer) and certain drugs). The invention presented herewith with no “EP1986678B1", with title “Solubility Enhancers that Contain Biguanide for Oral Peptide Delivery” and under classification number “A61K 38/23", is related to using certain aromatic alcohols as enhancers of absorption to facilitate transportation of peptides, proteins and macromolecules from the intestinal wall and specifically using new agents to enhance the solubility of the referred aromatic alcohols, with the objective to increase the existence of such agents inside the biologic fluids where they dissolve very little under normal conditions. Again the invention presented herewith with no “WO 1997/020568", with title “Compositions Containing Bismuth for Prevention and Treatment of Gastrointestinal Disorders" and under classification number “A61K 33/24", is related to administrating bismuth to a human or an animal for protective treatment and treatment of the human or the animal who has a gastrointestinal disorder caused or facilitated by algae and/ or cyanobacteria. Again the invention presented herewith with no “WO 2000/041719", with title " Using a Neurotrophin or its analogues for treatment of hypomotility related to gastrointestinal disorders” and under classification number “A61K 39/00", is related to methods specifically used for increasing gastrointestinal motility. The present invention is particularly related to using neurotrophin-3 and its analogues for increasing the gastrointestinal motility. The method regarding the use of neurotrophin-3 and its analogues for treatment of gastrointestinal hypomotility disorders is also provided. Again the invention presented herewith with no “EP2139882B1", with title " 3-Substituted Quinoline or Quinoxaline Derivatives and Using These as Phosphatidylinositol 3-Kinase (pı3k) Inhibitors" and under classification number “C07D 401/12", is related to the substituted bicyclic heteroaryl compounds having the structure shown in (I) or their pharmaceutically acceptable salts and compositions consisting of these, where X variable means C or N, and Y variable means N(R"), O or S, and referred compounds are useful in inhibiting the biological activity of PI3K5 enzyme of human origin and are intended for using treatment of general inflammation, arthritis, rheumatoid diseases, osteoarthritis, inflammatory intestinal disorders, inflammatory eye diseases, inflammatory and unstable bladder disorders, psoriasis, dermal complaints consisting of inflammatory components, chronic inflammatory cases, for example autoimmune diseases including but not limited with, systemic lupus erythematosus (SLE), myasthenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiple sclerosis, Sjogren’s Syndrome and autoimmune hemolytic anemia, and also treatment of allergic cases including all hypersensitivity forms. On the other hand, with the present invention methods are provided that are intended for treatment of cancer cases that develop through p1105 activity, depends on p1105 activity or is related to p1105 activity, including but not limited with, Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Myeloproliferative Diseases (MPD), Chronic Myeloid Leukemia (CML), T-Cell Acute Lymphoblastic Leukemia (T-ALL), B-Cell Acute Lymphoblastic Leukemia (B-ALL), Non-Hodgkin’s Lymphoma (NHL), B-cell lymphoma and solid tumors like breast cancer. To conclude it has become inevitable to proceed with a development in the area of the related technology, considering the inadequacy of the existing solutions and the need for a formulation intended for treatment of intestinal malabsorption. <strong>Objective of the Invention</strong> To overcome the disadvantages referred in the Background of the Related Technology, One objective of the present invention is, to enhance nutrition absorption by improving active cAMP increase; One other objective of the invention is to enhance amylase expression; One other objective of the invention is to enhance protease expression; One other objective of the invention is to improve insulin sensitivity; One other objective of the invention is to provide functional increase of GIUT 4 translocation at an effective rate. The present invention, which is aimed to achieve the above-mentioned advantages, is intended for treatment of intestinal malabsorption and is a formulation that is obtained by combination of the compositions selected in a single form or in combinations from a group containing; 16,20-bis(2-dimethyl)-6-O-stigmast-4-ene-coumaroyl-3-one, 2,3-bis(6-oxoethyl)-4-0-dioxin, 3,5-methoxy-stigmast-6-ene-phenyl-4-one. Structural and characteristic properties as well as all the advantages of the invention presented herewith will be clearly understood with the detailed description provided below and thus the evaluation regarding the present invention should be based on the detailed description presented herewith. <strong>Detailed Description of the Invention</strong> The present invention is related to a formulation developed for treatment of intestinal malabsorption. The referred formulation, enhances nutrition absorption by improving active cAMP increase, enhances amylase expression, enhances protease expression, improves insulin sensitivity, provides functional increase of GIUT 4 translocation at an effective rate. The formulation related to the present invention herewith contains; 16,20-bis(2-dimethyl)-6-O-stigmast-4-ene-coumaroyl-3-one, 2,3-bis(6-oxoethyl)-4-0-dioxin, 3,5-methoxy-stigmast-6-ene-phenyl-4-one. The referred formulation is formed by mixing the above-mentioned components at below percentages by weight; 11-33% of 16,20-bis(2-dimethyl)-6-O-stigmast-4-ene-coumaroyl-3-one, 26-45% of 2,3-bis(6-oxoethyl)-4-0-dioxin, 63-22% of 3,5-methoxy-stigmast-6-ene-phenyl-4-one. Components given above are obtained by combining the components from the above-mentioned group at the given range of weight ratios in a single form or in combinations thereof. The present invention at the same time is related to using the above-referred formulation for treatment of intestinal malabsorption and manufacturing it for such purpose. <strong>CLAIMS</strong> A formulation intended for treatment of intestinal malabsorption, which consists of combining the components selected from the group; 16,20-bis(2-dimethyl)-6-O-stigmast-4-ene-coumaroyl-3-one, 2,3-bis(6-oxoethyl)-4-0-dioxin, 3,5-methoxy-stigmast-6-ene-phenyl-4-one in a single form or in combinations thereof. The formulation of Claim 1 which is characterized by containing 11-33% of 16,20-bis(2-dimethyl)-6-O-stigmast-4-ene-coumaroyl-3-one by weight. The formulation of Claim 1 which is characterized by containing 26-45% of 2,3-bis(6-oxoethyl)-4-0-dioxin by weight. The formulation of Claim 1 which is characterized by containing 63-22% of 3,5-methoxy-stigmast-6-ene-phenyl-4-one by weight. Using the compositions obtained by selecting singly or in combination of components from the group of; 16,20-bis(2-dimethyl)-6-O-stigmast-4-ene-coumaroyl-3-one, 2,3-bis(6-oxoethyl)-4-0-dioxin, 3,5-methoxy-stigmast-6-ene-phenyl-4-one from any one as given in Claims 2-4 in manufacturing the formulation intended for treatment of intestinal malabsorption. <strong>SUMMARY</strong> <strong>A FORMULATION INTENDED FOR TREATMENT OF INTESTINAL MALABSORPTION</strong> The present invention is related to a formulation developed for treatment of intestinal malabsorption. The referred formulation, enhances nutrition absorption by improving active cAMP increase, enhances amylase expression, enhances protease expression, improves insulin sensitivity, provides functional increase of GIUT 4 translocation at an effective rate.